Need help now? Support now: crisis lines by country.

Questions about pain · Mathematical Institute for Research of Pain

The numbing drops took away some of my eye pain, but not all. What does that mean?

In an eye clinic, numbing drops can help show where eye pain comes from. Pain that goes away is taken to come mainly from the surface of the eye; pain that stays suggests that nerves further along the pain pathway are involved as well. It is a sign, not proof, and the drops are never for use at home.

I think there’s a pain somewhere in the room, … but I couldn’t positively say that I have got it.

Mrs. Gradgrind, in Charles Dickens, Hard Times, 1854, Book II, chapter IX · Source

The short answer

Anaesthetic eye drops, such as proparacaine, numb the nerve endings in the cornea, the clear front surface of the eye, for a short time. Some eye clinics use them as a one-off test for eye pain: you rate your pain, a drop goes into each eye, and you rate it again a few seconds later.

If the pain goes away completely, it is taken to come mainly from the surface. If it does not change, the pain is thought to come, at least in part, from further along the pain pathway, in the brain and spinal cord, which drops on the surface cannot reach. If it eases but does not go, as in your case, the usual reading is that both are involved, in different proportions.

Partial relief does not mean the remaining pain is imagined, or that you rated it wrongly. It is one clue among several, read beside the examination and your own account. Another page here asks why eye pain can be severe when the eye exam was normal.

The drops are for the clinic only. Doctors generally do not prescribe them for home use, because using them again and again can seriously damage the cornea.

What is known

In a 2017 review of neuropathic corneal pain, eye specialists Gabriela Dieckmann, Sunali Goyal and Pedram Hamrah describe this test, using proparacaine 0.5%. They write that the drops abolish pain arising in the corneal nerves but have no effect on pain from central sensitisation, the state in which pain-signalling nerve cells in the brain and spinal cord respond more strongly than usual. Complete or partial relief, they write, suggests that the pain is likely surface or mixed; no response suggests pain that is at least partly central. In their clinical experience, many patients get only partial relief, which suggests that both kinds are at work. They also note a limit: the test cannot tell apart dry-eye pain and pain from damaged surface nerves.

Crane and colleagues (2017) gave the test to 224 people with dry-eye symptoms at a veterans’ eye clinic in Miami. They rated their eye pain from 0 to 10, received one drop of proparacaine in each eye, and rated it again 15 seconds later. Forty-one still had some pain; most of them rated it low, between 1 and 3. Those whose pain persisted reported more burning and other nerve-like symptoms, and found heat and cold painful sooner on the skin of the forehead, which shares the eye’s nerve supply, and of the forearm, far from the eye; this skin testing was done in about half of them. Most of the signs seen on examining the eye’s surface did not differ between the groups.

Eye specialists at the Casey Eye Institute in Oregon have reviewed the harms of anaesthetic eye drops. Used as intended in a clinic, they write, the drops are remarkably safe, and they are generally not prescribed for use at home. Used again and again, they can cause wounds on the surface that do not heal, inflammation and clouding of the cornea, ulcers and, in severe cases, a hole through the cornea (McGee and Fraunfelder, 2007; Patel and Fraunfelder, 2013).

What is not yet known

There is no agreed line between partial relief and no relief. Crane’s study counted any pain left after 15 seconds, and the review describes the reading of partial relief partly from its authors’ clinical experience. Crane’s study looked at one moment in time, in a group that was mostly older men, and it took the persisting pain itself as its marker of central sensitisation, so it could not test that marker against anything more direct. Whether people with partial relief do better with one approach than another has not been settled by trials.

A single rating a few seconds after a drop also carries the ordinary uncertainty of any rating: what you expected, how the clinic felt, and how hard it is to judge a change so quickly.

What would tell us

Studies that repeat the test in the same people on different days, set the result beside images of the corneal nerves and tests of sensitivity elsewhere in the body, and follow people over months would show how steady the result is and what it predicts. Until then, the result is most useful written down beside your own description of the pain: what it feels like, what sets it off, and how it changes through the day. Nociflux’s free printable one-week eye pain and light log has room for that, day by day.

A worked example

A simple model with invented numbers. Suppose your pain before the drops is b=7b = 7 out of 10, and after the drops it is a=3a = 3. The share of the pain that went away is

b−ab=7−37≈0.57\dfrac{b - a}{b} = \dfrac{7 - 3}{7} \approx 0.57,

where bb is the rating before the drops, aa is the rating after, and b−ab - a is the drop in pain. In this model, a little over half of the pain behaved like pain from the surface, which the drops can reach, and the remaining 3 points behaved like pain from further along the pathway, which they cannot.

The model is a teaching picture. It assumes the two parts simply add up, that the drops silence the whole surface part, and that one rating catches it exactly. None of that is certain, which is why the result is read as a sign and not a measurement.

These pages explain reasoning and evidence. Nothing here is medical advice or a forecast about any person.

Sources

  1. Dieckmann G, Goyal S, Hamrah P. Neuropathic corneal pain: approaches for management. Ophthalmology. 2017;124(11S):S34–S47. doi:10.1016/j.ophtha.2017.08.004
  2. Crane AM, Feuer W, Felix ER, et al. Evidence of central sensitisation in those with dry eye symptoms and neuropathic-like ocular pain complaints: incomplete response to topical anaesthesia and generalised heightened sensitivity to evoked pain. Br J Ophthalmol. 2017;101(9):1238–1243. doi:10.1136/bjophthalmol-2016-309658
  3. McGee HT, Fraunfelder FW. Toxicities of topical ophthalmic anesthetics. Expert Opin Drug Saf. 2007;6(6):637–640. doi:10.1517/14740338.6.6.637
  4. Patel M, Fraunfelder FW. Toxicity of topical ophthalmic anesthetics. Expert Opin Drug Metab Toxicol. 2013;9(8):983–988. doi:10.1517/17425255.2013.794219

Pain words: Corneal neuropathic pain · Photoallodynia · Central sensitisation · Allodynia · All words

Related, in Nociflux, the Institute’s ecosystem for living with pain: its features for eye pain and light sensitivity.

Inside the Institute

The Pain Bias Codex gathers checks on conclusions about pain, in four families. With an invite code you can read this check there beside the others, with its full evidence notes. Pain math explains what the Institute does.

No code yet? Ask for an invite. A person reads every request and writes back by hand with an invite code, so it may take a few days.

Need help now? Support now: crisis lines by country.

Except where a page says otherwise, the Institute’s own text and figures are shared under CC BY-NC 4.0. Pictures and quotations from others keep their own credits and licences.

Back to the invite page · Sign in

Paper